Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.33), $0.09 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $1 million versus the consensus estimate of $590 thousand.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.